Transcriptomics effects of ALDH1A3 inhibitor,CLM296, in MDA-MB-231 Triple negative breast cancer cells

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor survival outcomes. Aldehyde dehydrogenase 1A3 (ALDH1A3) promotes tumor growth, metastasis, and chemoresistance across multiple cancer types including TNBC, glioblastoma, melanoma lung, and colon cancers. Currently, there are no ALDH1A3 inhibitors in clinic and developing targeted ALDH1A3 inhibitors is novel precision medicine approach to treat ALDH1A3+ tumors. For this purpose, we have developed a novel ALDH1A3 specific inhibitor,CLM296 Overall design: MDA-MB-231 breast cancer cells, overpressing ALDH1A3 or vector control, were treated with or without 100nM CLM296 for 24 hours. The RNA was collected and sequencing was performed on Illumina NovaseqX platform. Three replicates per sample were used in this study.